Alasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
|
|
- Brett Sharp
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (1999) 43, JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility Alasdair P. MacGowan*, Mandy Wootton and H. Alan Holt Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration time curve (AUC) for an equivalent dose. It has been proposed that the AUC/MIC ratio is a general predictor of antibacterial efficacy for quinolones. Using an in-vitro kill curve technique, performed in quadruplicate, with nine antibiotic concentrations and three strains of P. aeruginosa with varying quinolone susceptibility, we constructed sigmoidal dose response curves for AUC /MIC and area under the bacterial kill curve (AUBKC) or AUC 0 24 /MIC and log change in viable count at 24 h ( 24). For levofloxacin the log AUC /MIC ratio to produce 50% of the maximal effect was 0.74 ± 0.13 (r 2 = ) for levofloxacin and 0.82 ± 0.06 (r 2 = ) for ciprofloxacin. The log AUC 0 24 /MIC ratio to produce 50% maximal effect was 1.58 ± 0.13 (r 2 = ) for levofloxacin and 1.37 ± 0.12 (r 2 = ) for ciprofloxacin. An AUC 0 24 /MIC ratio of 125 produced 85.4% of the maximal response with levofloxacin and 81.5% with ciprofloxacin. These data suggest that levofloxacin and ciprofloxacin have equivalent activity against P. aeruginosa at equivalent AUC/MIC ratios. Introduction The main pharmacodynamic predictor of antibacterial efficacy for ciprofloxacin is the ratio of drug exposure as defined by concentration and time divided by the ciprofloxacin susceptibility of the pathogen as indicated by the MIC. The use of in-vitro pharmacodynamic models has indicated that the area under the serum concentration time curve (AUC)/MIC ratio can be related to bacterial killing for ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin (BAY ). 1 4 The parameter used to measure bacterial killing is of critical importance in these calculations and the area under the bacterial kill curve (AUBKC) or a derivative has gained some acceptance though other parameters are used. 2,4,6,7 In addition there are data to show that it is not crucial whether ciprofloxacin, levofloxacin and ofloxacin are dosed once or twice a day; their antibacterial effects are similar provided they have a similar AUC/MIC ratio. 1,8 However, some in-vitro and animal data favour maximum serum concentration (C max )/MIC ratios as determining outcome but this effect may be of secondary importance to the AUC/ MIC Furthermore, human data from ITU pneumonia and COPD exacerbations indicate that an AUC/MIC ratio of 125 is related to pathogen clearance and clinical outcome. 12,13 From these data it can be speculated that, provided quinolones have the same AUC/MIC ratio, they will be equally effective in laboratory models or clinical practice. However, this assumes that all quinolones kill different bacterial species in an equivalent way. This is not the case with pneumococci even if the MICs are similar. 14 The purpose of this study was to compare the bactericidal activity of levofloxacin and ciprofloxacin against Pseudo - monas aeruginosa by using a sigmoid exposure response model, to determine the 50% AUC/MIC ratios for lethal effect for each agent. *Corresponding author. Tel: ; Fax: The British Society for Antimicrobial Chemotherapy 345
2 A. P. MacGowan et al. Materials and methods Three bacterial strains were used with varying quinolone susceptibilities, P. aeruginosa strain 5761 being the most susceptible, strain of intermediate susceptibility, and strain 8545 the least susceptible. MICs were determined for levofloxacin and ciprofloxacin in a macrobroth dilution method using Isosensitest broth and increases in drug concentration of 0.1 mg/l. Levofloxacin (Hoechst Marion Roussel, Uxbridge, UK) and ciprofloxacin (Bayer PLC, Newbury, UK) were used. In the time kill curve experiments they were used at concentrations of 0.25, 0.5, 1, 2, 3, 4, 5, 6 and 10 mg/l. The kill curves were performed by a modification of established technique. 15 Twentymillilitre Isosensitest broths (Unipath, Basingstoke, UK), were inoculated to give a final inoculum of 10 6 cfu/ml. For each antimicrobial a set of ten broths was incorporated with the required antibiotic concentration plus a growth control. These were sampled and diluted as necessary, and viable counts were performed using a spiral plater (Spiral System; Don Whitley, Shipley, UK) at time 0, then every 30 min up to 2.5 h, then hourly up to 6.5 h, and finally at 24 h. Counts were obtained on nutrient agar plates containing 0.1% magnesium chloride which inactivated any residual antibiotic. Viable counts were read manually after incubation at 37 C for 24 h. Each kill curve was performed in quadruplicate. Data analysis Time kill curves were drawn by plotting log cfu/ml against time in hours. The AUBKC for h was calculated using the Graph Pad Prism software package (Graph Pad Software Inc., San Diego, CA, USA). The AUBKC was determined by the trapezoid rule. Drug exposure was calculated by multiplying the quinolone concentrations by 6.5 h or 24 h then dividing by the MIC for the strain to give an AUC /MIC ratio or AUC 0 24 /MIC ratio. A sigmoidal dose response with HILLSLOPE 1.0 was fitted to the data for log AUC /MIC and AUBKC or log AUC 0 24 /MIC and log change in viable count at 24 h ( 24). The minimum and maximum values, log AUC/MIC producing the 50% response between the maximum and minimum responses, and r 2 were calculated. The percentage of maximal response produced by an AUC 0 24 /MIC of 125 was read off the dose response curve for each drug. Results The three strains of P. aeruginosa used had levofloxacin MICs of 0.8 mg/l (strain 5761), 0.12 mg/l (strain 11683) and 4 mg/l (strain 8545); the equivalent MICs of ciprofloxacin were 0.09 mg/l (5761), 0.6 mg/l (11683) and 1.2 mg/l (8545). As might be expected because of lower ciprofloxacin MIC values, the degree of killing at equivalent quinolone concentrations in the kill curves was usually significantly superior with ciprofloxacin than with levofloxacin (Table). With strain 5761, the most quinolone-susceptible, this was only apparent at concentrations of 0.5 mg/l as at greater concentrations the strain was rapidly killed by both drugs. For strain 11683, which was of intermediate susceptibility, and strain 8545, the least susceptible, both agents were equivalent at low concentration as little killing occurred Table. Area under the bacterial time kill curve (AUBKC) for three strains of P. aeruginosa exposed to levofloxacin or ciprofloxacin at fixed concentrations for 6.5 h AUBKC (log cfu/ml.h) strain 5761 strain strain 8545 Concentration (mg/l) levofloxacin ciprofloxacin levofloxacin ciprofloxacin levofloxacin ciprofloxacin a a a a a a a a a a a a a a a a a P 0.05, Mann Whitney U test. Respective levofloxacin and ciprofloxacin MICs were as follows: strain 5761, 0.8 and 0.09 mg/l; strain 11683, 1.2 and 0.6 mg/l; strain 8545, 4 and 1.2 mg/l. 346
3 Levofloxacin vs ciprofloxacin against P. aeruginosa with either drug, but at higher concentrations ciprofloxacin was more bactericidal than levofloxacin as measured by AUBKC (Table). A dose response curve was fitted to the data using AUC /MIC ratio and AUBKC. This allowed the drugs bactericidal properties to be compared taking into account ciprofloxacin s lower MIC. The log AUC /MIC to produce 50% of the maximal effect was (95% CI, ; r ) for levofloxacin and (95% CI, ; r ) for ciprofloxacin. The maximum AUBKC for the levofloxacin AUC /MIC responses was (95% CI, ) and the minimum (95% CI, 5.2 to 2.0). Equivalent values for ciprofloxacin were: maximum, (95% CI, ); minimum (95% CI, 6.9 to 2.6) (Figure 1). A similar log AUC 0 24 /MIC response curve was calculated using 24. The log AUC 0 24 /MIC ratio required to produce 50% of the maximum growth was (95% CI, , r ) for levofloxacin and (95% CI, , r ) for ciprofloxacin. The maximum 24 was (95% CI, ) for levofloxacin and (95% CI, ) for ciprofloxacin. Minimum values were (95% CI, ) for levofloxacin and (95% CI, ) for ciprofloxacin (Figure 2). An AUC 0 24 /MIC of 125 produced 85.4% of the maximal response for levofloxacin and 81.5% for ciprofloxacin. Discussion It is already known that levofloxacin has higher MIC values than ciprofloxacin and is less bactericidal at equivalent concentrations against P. aeruginosa. However, the main determinant of outcome with quinolones is the drug exposure modified by the pathogen s susceptibility. Pharmacokinetic data indicate that a single 500 mg dose of levofloxacin produces an AUC of 45.6 mg/l/h, while an equivalent dose of ciprofloxacin produces one of 9.9 mg/l/h. 16,17 Multiple doses of 500 mg levofloxacin and ciprofloxacin also produce AUC 0 24 values which are approximately four times greater for levofloxacin than for ciprofloxacin. 18,19 Ciprofloxacin is about four times more active than levofloxacin in terms of mean MIC, MIC 50 and MIC 90 for P. aeruginosa, including strains isolated in the UK (Fish & Chow; 18 D. Felmingham, personal communication), hence, it is likely that, in the treatment of P. aeruginosa, levofloxacin and ciprofloxacin will have similar AUC/MIC ratios. Data from in-vitro models using P. aeruginosa indicate that for ofloxacin and ciprofloxacin the AUC/MIC thresholds required to produce a maximum bacterial effect as measured by AUBKC are the same. 4 However, when ofloxacin and ciprofloxacin were modelled Figure 1. (a) Levofloxacin and (b) ciprofloxacin against three strains of P. aeruginosa: relationship between AUC /MIC and AUBKC. Figure 2. (a) Levofloxacin and (b) ciprofloxacin against three strains of P. aeruginosa: relationship between AUC 0 24 /MIC and 24; an AUC/MIC ratio of 125 is marked by the vertical broken line. 347
4 A. P. MacGowan et al. simulating pharmacologically achievable concentrations, then ciprofloxacin was superior to ofloxacin, but AUC/ MIC ratios were not comparable and favoured ciprofloxacin. 5 Data using Staphylococcus aureus would also support the concept that, provided the AUC/MIC ratios were similar, levofloxacin and ciprofloxacin have similar bactericidal activity in an in-vitro model. 8 A sigmoid E max model has been used previously to study the bactericidal activity of ciprofloxacin but the rate of kill was compared with the concentration/mic ratio so the data are not comparable to our own. 20 These data indicate that, provided the AUC/MIC ratios are equivalent, then the bactericidal activities of levofloxacin and ciprofloxacin are equivalent, hence an AUC 24 /MIC ratio of 125 produced an 80 85% maximal response with both agents and the log E 50 are equivalent. This may not be true of all pathogen groups as it has been suggested that levofloxacin is more bactericidal than ciprofloxacin against Streptococcus pneumoniae. 14 Our data, in conjunction with many other findings, suggest that in the therapy of P. aeruginosa, ciprofloxacin and levofloxacin will be equally active, provided the drug exposure/mic ratios are the same. This would seem likely given the pharmacokinetics and in-vitro susceptibilities of these agents. Acknowledgement We would like to thank Mr M. Barlow of Hoechst Marion Roussel for his support in performing this study. References 1. MacGowan, A. P. & Bowker, K. E. (1998). Sequential antimicrobial therapy, pharmacokinetic and pharmacodynamic considerations in sequential therapy. Journal of Infection (in press). 2. Bowker, K. E., Wootton, M., Holt, H. A., Reeves, D. S. & MacGowan, A. P. (1997). Bactericidal activity of Bay against Streptococcus pneumoniae explored using an in vitro continuous bacterial culture model. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstract F-134, p American Society for Microbiology, Washington, DC. 3. Madaras-Kelly, K. J., Larsson, A. J. & Rotschafer, J. C. (1996). A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy Madaras-Kelly, K. J., Ostergaard, B. E., Hovde, L. B. & Rotschafer, J. C. (1996). Twenty-four-hour area under the concentration time curve/mic ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, Firsov, A. A., Vostrov, S. N., Shevchenko, A. A. & Cornaglia, G. (1997). Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 41, MacGowan, A. P., Wootton, M., Hedges, A. J., Bowker, K. E., Holt, H. A. & Reeves, D. S. (1996). A new time kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, aminoglycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy 38, Bowker, K. E., Holt, H. A., Reeves, D. S. & MacGowan, A. P. (1996). Pharmacodynamics of meropenem as explored by use of a single compartment in vitro continuous bacterial culture model to simulate once, twice and three times a day dosing. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Abstract 46, p. 9. American Society for Microbiology, Washington, DC. 8. Kang, S. L., Rybak, M. J., McGrath, B. J., Kaatz, G. W. & Seo, S. M. (1994). Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin, alone and in combination with rifampin, against methicillin susceptible and resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial Agents and Chemotherapy 38, Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, Drusano, G. L., Johnson, D. E., Rosen, M. & Standford, H. C. (1993). Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 37, Sullivan, M. C., Cooper, B. W., Nightingale, C. H., Quintiliani, R. & Lawlor, M. T. (1993). Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrobial Agents and Chemotherapy 37, Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, Forrest, A., Amantea, M., Collins, D. A., Chodosh, S. & Schentag, J. J. (1993). Pharmacodynamics of oral OPC in patients with acute bacterial exacerbations of chronic bronchitis. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Abstract 81, p American Society for Microbiology, Washington, DC. 14. George, J. & Morrissey, I. (1997). The bactericidal activity of levofloxacin and other fluoroquinolones against Streptococcus pneumoniae. Clinical Microbiology and Infection 3, Suppl. 2, Krogstad, D. J. & Moellering, R. C. (1986). Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 2nd edn (Lorian, V., Ed.), pp , William & Wilkins, Baltimore, MD. 16. Holland, M. L., Chien, S.-C., Corrado. M. L. et al. (1994). The pharmacokinetic profile of levofloxacin following once-or twice-daily 500 mg oral administration of levofloxacin hemihydrate. In Abstracts of the Fifth International Symposium on New Quinolones, Singapore, Abstract
5 Levofloxacin vs ciprofloxacin against P. aeruginosa 17. Bergan, T., Thorsteinsson, S. B., Solberg, R., Bjornskau, L., Kolstad, I. M. & Johnsen, S. (1987). Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. American Journal of Medicine, 82, Suppl. 4A, Fish, D. N. & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics 32, Wilson, A. P. R. & Grüneberg, R. N. (Eds) (1997). C i p r o flo x a c i n: 10 years of clinical experience, pp Maxim Medical, Oxford. 20. Hyatt, J. M., Nix, D. E., Stratton, C. W. & Schentag, J. J. (1995). In vitro pharmacodynamics of piperacillin, piperacillin tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, Received 3 February 1998; returned 23 March 1998; revised 7 April 1998; accepted 7 May
6
Alasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationAUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Journal of Antimicrobial Chemotherapy (2002) 50, 533 539 DOI: 10.1093/jac/dkf177 AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationReceived 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
Journal of Antimicrobial Chemotherapy (2003) 51, 905 911 DOI: 10.1093/jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationA. P. MacGowan*, M. Wootton, A. J. Hedges, K. E. Bowker, H. A. Holt and D. S. Reeves
Journal of Antimicrobial Chemotherapy (996) 8, 9-0 A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative /Mactam, aminoglycoside
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationCollege of Pharmacy, University of Minnesota, Minneapolis, Minnesota, 1 and St. Paul-Ramsey Medical Center, St. Paul, Minnesota 2
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1996, p. 627 632 Vol. 40, No. 3 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Twenty-Four-Hour Area under the Concentration-Time Curve/MIC
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationPharmacodynamics of fluoroquinolones. A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box , Wuppertal, Germany
Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. B, 51 59 Pharmacodynamics of fluoroquinolones JAC A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box 101709, 42096 Wuppertal, Germany Fluctuating
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationUse of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationIN VITRO ANTIBACTERIAL EFFECT OF ENROFLOXACIN DETERMINED BY TIME-KILLING CURVES ANALYSIS
Bulgarian Journal of Veterinary Medicine (2010), 13, No 4, 218 226 IN VITRO ANTIBACTERIAL EFFECT OF ENROFLOXACIN DETERMINED BY TIME-KILLING CURVES ANALYSIS Summary A. M. HARITOVA 1 & N. V. RUSSENOVA 2
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationJAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationAdvance Access published September 16, 2004
Advance Access published September 16, 2004 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkh435 JAC Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationDose Ranging and Fractionation of Intravenous Ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an In Vitro Model of Infection
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1993, p. 1756-1763 Vol. 37, No. 9 66-484/93/91756-8$2./ Copyright X 1993, American Society for Microbiology Dose Ranging and Fractionation of Intravenous Ciprofloxacin
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationIn vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
Advance Access published April 14, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg238 In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationGUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ANTIMICROBIAL ASSAY SERVICE. 18th Edition
ANTIMICROBIAL REFERENCE LABORATORY ANTIMICROBIAL ASSAY SERVICE GUIDELINES FOR USERS 18th Edition 2015 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology
More informationComparative Study of the Mutant Prevention Concentration of Moxifloxacin, Levofloxacin and Gemifloxacin against Pneumococci.
AAC Accepts, published online ahead of print on 14 December 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01353-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationComparison of Efficacies of Oral Levofloxacin and Oral Ciprofloxacin in a Rabbit Model of a Staphylococcal Abscess
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1999, p. 667 671 Vol. 43, No. 3 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of Efficacies of Oral
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEvaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations
J Antimicrob Chemother 2012; 67: 2207 2212 doi:10.1093/jac/dks195 Advance Access publication 30 May 2012 Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic
More informationORIGINAL ARTICLE /j x. Institute, São Paulo, Brazil
ORIGINAL ARTICLE 1.1111/j.1469-691.27.1885.x Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationCF WELL Pharmacology: Microbiology & Antibiotics
CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure
More informationIn vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Journal of Antimicrobial Chemotherapy Advance Access published February 8, 2007 Journal of Antimicrobial Chemotherapy doi:.93/jac/dkl52 In vitro pharmacodynamics of colistin against Acinetobacter baumannii
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationReceived 20 August 2003/Returned for modification 12 July 2003/Accepted 15 November 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 946 953 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.946 953.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationStreptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 794 799 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.794 799.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationCeftaroline versus Ceftriaxone in a Highly Penicillin-Resistant Pneumococcal Pneumonia Rabbit Model Using Simulated Human Dosing
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3557 3563 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01773-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Ceftaroline
More informationShape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa
J Antimicrob Chemother 15; 7: 1 doi:1.193/jac/dku37 Advance Access publication November 1 Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationDetermination of antibiotic sensitivities by the
Journal of Clinical Pathology, 1978, 31, 531-535 Determination of antibiotic sensitivities by the Sensititre system IAN PHILLIPS, CHRISTINE WARREN, AND PAMELA M. WATERWORTH From the Department of Microbiology,
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationPostantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method
Journal of Antimicrobial Chemotherapy (1988) 22, 23-33 Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Barforo Isaksson'*, Lennart Nibson*, Rolf Mailer' and
More informationPharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient
Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationImpact of Spores on the Comparative Efficacies of Five Antibiotics. Pharmacodynamic Model
AAC Accepts, published online ahead of print on 12 December 2011 Antimicrob. Agents Chemother. doi:10.1128/aac.01109-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationTreatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis
Journal of Antimicrobial Chemotherapy (2003) 52, 668 674 DOI: 10.1093/jac/dkg403 Advance Access publication 1 September 2003 Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationPharmacological indices in antibiotic therapy
Advance Access published November 12, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg482 Pharmacological indices in antibiotic therapy Antina Barger, Christine Fuhst and Bernd Wiedemann*
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationGARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1999, p. 29 34 Vol. 43, No. 1 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Two Pharmacodynamic Models for Assessing
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationparameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an
Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More information